Company profile
Aktis Oncology, Inc.
Pipeline2 assets
- AKY-1189AKY-1189 / Nectin-4 / miniprotein radioconjugate; 225Ac targeted alpha radiopharmaceutical / OncologyNectin-4 expressing solid tumorsPhase 1bongoingUSLocally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer, cervical cancer, head and neck cancerPhase 1bongoingUS
- AKY-2519AKY-2519 / B7-H3 (CD276) / miniprotein radioconjugate; 225Ac targeted alpha radiopharmaceutical; 64Cu imaging pair / OncologyMetastatic castration-resistant prostate cancerPhase 1bongoingUSB7-H3 expressing solid tumors, including lung and colorectal cancerPhase 1bplannedUS
Latest news0 items
All newsNo recent headlines yet.
New company coverage will appear here as soon as it is picked up.